Tiotropium
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Tiotropium: From Inhaled Bronchodilator to Obstructive Lung Disease
One-Sentence Summary
Tiotropium is a long-acting inhaled antimuscarinic bronchodilator that is already registered and marketed in South Africa. The TxGNN model predicts it may be effective for obstructive lung disease, and this prediction is supported by more than 40 registered clinical trials and 20 publications, including several large Phase 3 RCTs. The evidence is strong, but most of it comes from COPD, so this is probably an on-label use rather than a true repurposing finding.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Obstructive lung disease |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L1 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 5 |
| Recommended Decision | Proceed with Guardrails |
The approved indication text was not available in the registration records supplied, so the original indication is not listed.
Why is This Prediction Reasonable?
Tiotropium blocks muscarinic M1, M2 and M3 receptors. It dissociates slowly from M3 receptors, which sit on airway smooth muscle, so it works for a long time and can be given once daily. Blocking M3 relaxes airway smooth muscle and reduces cholinergic bronchoconstriction and mucus secretion. Structured mechanism-of-action data were not available in the Evidence Pack, so this description is drawn from the published drug reviews retrieved (for example PMID 12010082).
Obstructive lung disease is the broad disease group that includes COPD and, to a degree, asthma. Cholinergic tone drives airflow limitation in these conditions, so the mechanism fits directly. The trial evidence is consistent with this: tiotropium has been studied mainly in COPD, and also in severe persistent asthma, obliterative bronchiolitis and childhood wheezing.
The high TxGNN score is therefore biologically plausible. However, the SAHPRA-registered products (Spiriva Respimat and the HandiHaler-type capsules) sit in the respiratory bronchodilator category. This prediction should be verified against the approved Professional Information (PI) before it is counted as a repurposing candidate.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00144339 | Phase 3 | Completed | 5,993 | Placebo-controlled trial of whether tiotropium 18 mcg daily reduces the rate of lung function decline in COPD |
| NCT00277264 | Phase 3 | Completed | 914 | SAFE: 48-week effect of tiotropium on trough FEV1 vs placebo, by smoking status |
| NCT00274014 | Phase 3 | Completed | 1,000 | One-year effect of tiotropium on lung function and exacerbations in COPD |
| NCT02172287 | Phase 3 | Completed | 623 | Six-month comparison of tiotropium, salmeterol and placebo on bronchodilation and quality of life |
| NCT01316913 | Phase 3 | Completed | 872 | 24-week study of a GSK combination inhaler vs tiotropium as comparator |
| NCT01012765 | Phase 3 | Completed | 173 | Indacaterol vs placebo on inspiratory capacity in moderate COPD, with open-label tiotropium as active control |
| NCT00776984 | Phase 3 | Completed | 453 | 48-week add-on tiotropium Respimat vs placebo in severe persistent asthma |
| NCT00523991 | Phase 4 | Completed | 457 | 24-week tiotropium HandiHaler vs placebo in COPD patients naive to maintenance therapy |
| NCT01112241 | Phase 4 | Completed | 17 | Acute bronchodilator response to albuterol then tiotropium in obliterative bronchiolitis after stem cell transplant |
| NCT03199976 | Phase 4 | Terminated | 80 | Intermittent tiotropium in early childhood wheezing; early termination limits interpretation |
No SANCTR or PACTR identifiers were available in the Evidence Pack.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28877027 | 2017 | RCT | N Engl J Med | Tested whether long-term tiotropium improves lung function and slows its decline in mild-to-moderate COPD |
| 29605624 | 2018 | RCT | Lancet Respir Med | DYNAGITO: tiotropium plus olodaterol vs tiotropium alone for preventing COPD exacerbations |
| 25046211 | 2014 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Updated review of tiotropium vs placebo, including Respimat trials |
| 26391969 | 2015 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Updated comparison of tiotropium with ipratropium bromide in stable COPD |
| 19402836 | 2009 | Meta-analysis | Respirology | Efficacy and safety of tiotropium in Chinese patients with stable COPD |
| 40530954 | 2025 | Systematic review and meta-analysis | Expert Rev Respir Med | Effect of fixed-dose tiotropium/olodaterol on exercise-related outcomes in COPD |
| 32727455 | 2020 | Review | Respir Res | Clinical development of tiotropium; LAMA monotherapy is a recommended initial treatment in GOLD groups B, C and D |
| 33095662 | 2021 | Review | Curr Med Res Opin | Evidence for tiotropium + olodaterol in reducing COPD exacerbations |
| 12010082 | 2002 | Drug profile | Drugs | Slow M3 dissociation supports once-daily dosing; 18 mcg daily significantly improved lung function in COPD |
| 10069510 | 1999 | Review | Life Sci | Mechanistic and clinical profile of tiotropium in obstructive lung disease |
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 51/10.2.1/1120 | Tiotor 10 | Capsule |
| Reg. No. 50/10.2.1/0671 | Tiores | Capsule |
| Reg. No. 36/10.2.1/0045 | Forvent (refill) | Capsule |
| Reg. No. 36/10.2.1/0045 | Forvent HandiHaler complete with 30 inhalations | Kit |
| Reg. No. 41/10.2.1/0849 | Spiriva Respimat inhaler, 60 doses | Inhaler |
The Forvent capsule refill and the Forvent kit share one registration number. Approved indication text and Essential Medicines List status were not available in the Evidence Pack.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug interaction records were found. The literature retrieved for the COPD prediction also raises the following topics. These are signals to review, not confirmed conclusions:
- Cardiovascular risk: a meta-analysis of RCTs (PMID 32274526) examined tiotropium and adverse cardiovascular events.
- Dementia risk: a 2025 cohort study (PMID 40388132) examined whether tiotropium initiation is linked to dementia risk.
- Ocular effects: studies (PMID 39198799, NCT06525051) examined effects on anterior chamber parameters and intraocular pressure.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 RCTs and Cochrane reviews support tiotropium in obstructive airway disease, and the drug is already marketed in South Africa. The main caution is that this is likely an established use rather than a new one, and safety data for the South African products are missing.
The other predictions in the Evidence Pack are weaker. COPD (rank 5) is also L1 and on-label. The severe early-onset COPD subtype (rank 4) has only indirect evidence and is a research question. Respiratory malformation and the other structural, radiologic or rare-immunodeficiency predictions have no supporting evidence and are best held.
To proceed, the following is needed:
- The SAHPRA package insert warnings and contraindications, which are currently blocking the safety screen
- Confirmation of the approved indications on the PI, to establish whether this is on-label use
- Structured mechanism-of-action data from DrugBank
- A review of cardiovascular, anticholinergic and ocular safety signals before any expansion to new populations, such as asthma or paediatric wheezing
This report is for research reference only and does not constitute medical advice. Any repurposing candidate requires clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.